戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ommon gamma chain and thereby suppresses its oncogenic potential.
2 n through integration, and low mutagenic and oncogenic potential.
3 ity to interact with C-Raf exhibits elevated oncogenic potential.
4 min, a nucleolar protein believed to possess oncogenic potential.
5 wth and suppressed apoptosis, suggesting its oncogenic potential.
6  4 (IRF-4) is a transcription factor and has oncogenic potential.
7 Ras2/TC21, and R-Ras3/M-Ras) has significant oncogenic potential.
8 e hematopoietic cells and confer significant oncogenic potential.
9 utations that, in combination, have enhanced oncogenic potential.
10 NA have prognostic value and that a tRNA has oncogenic potential.
11 odes 81 open reading frames, several bearing oncogenic potential.
12 iant with constitutive GEF activity and high oncogenic potential.
13 clin D1 protein with significantly increased oncogenic potential.
14 e with one another and together exhibit high oncogenic potential.
15 ced antigenicity/immunogenicity and enhanced oncogenic potential.
16 and activator of transcription 3 (STAT3) has oncogenic potential.
17 ulating its function and contributing to its oncogenic potential.
18 of the protein-synthesizing machinery having oncogenic potential.
19 IkappaB inhibition are crucial to its strong oncogenic potential.
20 ation to modulate a cell's proliferative and oncogenic potential.
21 g pathways as an approach for preventing its oncogenic potential.
22                 It has been shown to possess oncogenic potential.
23 cytokine stimulation, has been shown to have oncogenic potential.
24 l GTPases TC21 and R-Ras that controls their oncogenic potential.
25  underscores the biochemical basis for their oncogenic potential.
26  activity toward p53, thereby increasing its oncogenic potential.
27  shown to be irrelevant to the activation of oncogenic potential.
28 nd AP-1 sequence elements, but vary in their oncogenic potential.
29 eobox genes, Pbx and Meis, accentuates their oncogenic potential.
30 hus providing a mechanism for regulating Lbc oncogenic potential.
31 t to establish which, if any, have intrinsic oncogenic potential.
32 sine kinase receptor, thereby unleashing its oncogenic potential.
33 function and, in the case of v-cbl, with its oncogenic potential.
34 lecular mechanism that may contribute to its oncogenic potential.
35 ns in Ras are poorly characterized for their oncogenic potential.
36 ivate CDC42, Rac1, and RhoA also demonstrate oncogenic potential.
37 rming proteins, correlates strongly with the oncogenic potential.
38 rphan" receptor tyrosine kinases (RTKs) with oncogenic potential.
39 ies, suggesting that acetylation of MEK1 has oncogenic potential.
40 topoietic stem cell function and restraining oncogenic potential.
41  need to better understand the virus and its oncogenic potential.
42 ated with the absence of FXR, suggesting its oncogenic potential.
43 ies than anticipated, forming a continuum of oncogenic potential.
44 and inactive conformations are linked to its oncogenic potential.
45 for EBV, a widespread human herpesvirus with oncogenic potential.
46 rved transcriptional coactivator with potent oncogenic potential.
47 ed stem cell derivatives are truly devoid of oncogenic potential.
48 N, much of the focus on PI3K has been on its oncogenic potential.
49 of SC self-renewal have been evinced to show oncogenic potential.
50  the control of HER-2 after it acquires full oncogenic potential.
51  (PyVs) are small DNA pathogens that contain oncogenic potentials.
52 establishing the mechanism(s) underlying its oncogenic potential and effect on the development of the
53 riptional effector mechanism to activate its oncogenic potential and further support a role for fusio
54  variants that explains the heterogeneity of oncogenic potential and geographic distribution.
55 s of the Wnt family of secreted factors have oncogenic potential and important roles as developmental
56                Furthermore, JCV possesses an oncogenic potential and induces development of various n
57  or hTERT activation but does correlate with oncogenic potential and is essential for induction of ep
58                       Epstein-Barr virus has oncogenic potential and is implicated in the development
59 ies of mutant FGFRs may normally limit their oncogenic potential and may be relevant to their ability
60 MiRNAs encoded by the mir-17-92 cluster have oncogenic potential and others may act as tumour suppres
61           Ongoing studies seek to define its oncogenic potential and pathogenesis.
62 -Myc, N-Myc and L-Myc), each with documented oncogenic potential and similar DNA binding properties.
63 demonstrated that ERBB4-truncated forms show oncogenic potentials and that ERBB4 pharmacologic inhibi
64 1 is a tumor recurrence-associated gene with oncogenic potential, and the interaction between BTB/POZ
65 the molecular mechanisms responsible for its oncogenic potential are still largely unknown.
66 ed under physiological control have enhanced oncogenic potential beyond the simple loss of p53 functi
67 f the myristylation signal not only enhanced oncogenic potential but also increased kinase activities
68 x and Myc form a heterodimer that has strong oncogenic potential but can also repress transcription,
69 ells that have acquired mutations with known oncogenic potential but, nevertheless, may show no manif
70 ssion, the wild-type p110alpha isoform lacks oncogenic potential, but gain-of-function mutations and
71                                    Raf-1 has oncogenic potential, but is normally controlled by a com
72          Further, these cell lines displayed oncogenic potential by exhibiting increased proliferatio
73 cer cells and that this contributes to their oncogenic potential by promoting chemoresistance.
74           We propose that the acquisition of oncogenic potential by the v-Erb A protein was a multist
75 arching for STRA13-interacting proteins with oncogenic potential by the yeast two-hybrid screening, w
76 s with cancer progression and acquisition of oncogenic potential by transformed rodent cells.
77        We conclude that AID activity and its oncogenic potential can be downregulated by phosphorylat
78 GFR3, TSC2 and RASGRP2 contribute to greater oncogenic potential compared with corresponding European
79 rent human tumor viruses indicate that their oncogenic potential depends in part on a common ability
80  to previous reports, tumors bearing higher "oncogenic potential" do not cluster in codon 41 of Catnn
81 ancy, including B cell lymphomas, and it has oncogenic potential downstream of STAT3.
82 fied a network gathering several miRNAs with oncogenic potential (eg, miR-155-5p) and targeted genes
83 BV-associated tumors and is reported to have oncogenic potential, enforced expression of EBNA-1 alone
84 DOT1L inhibition, and demonstrated increased oncogenic potential ex vivo and in secondary transplant
85                         Consistent with this oncogenic potential, exogenous CtBP2 transformed primary
86 egulating beta-catenin, underscoring a novel oncogenic potential for AURKA in gastric tumorigenesis.
87              Our results support an enhanced oncogenic potential for such mutations in human populati
88 s of cancer cells, and the regulation of its oncogenic potential has been widely studied.
89 in leukemia stem cell (LSC) self-renewal and oncogenic potential have been well defined; however, the
90 ecognized viruses include not only some with oncogenic potential (hepatitis B virus, rhesus papilloma
91 rt a mechanism by which an altered RTK gains oncogenic potential in a glioblastoma cell line.
92 mediated Bmi1 phosphorylation, enhancing its oncogenic potential in an Ink4a/Arf-independent manner.
93 d cyclin-dependent kinase (CDK) activity has oncogenic potential in breast cancer due to its ability
94                    We conclude that Skp2 has oncogenic potential in breast epithelial cells and is ov
95  ligand, suggesting that there may be latent oncogenic potential in dysregulated endomembrane traffic
96 MicroRNAs (miRNA) have tumor suppressive and oncogenic potential in human cancer, but whether and how
97                            This confirms its oncogenic potential in human cells and affords novel ins
98 ilms' tumor suppressor gene, but it may have oncogenic potential in leukemia and in some solid tumors
99 which the proto-oncogene c-myb can exert its oncogenic potential in myeloid lineage hematopoietic cel
100 , and in human cancer cells, increases their oncogenic potential in nude mice as reflected by a short
101 uisition of anchorage-independent growth and oncogenic potential in nude mice.
102         Thus, the TRPV6 channel acquires its oncogenic potential in PCa due to the remodeling mechani
103                                              Oncogenic potential in prostate cancer is modulated in p
104 activating genetic elements and tested their oncogenic potential in rodent cell transformation models
105 etheless, there is no direct evidence of its oncogenic potential in T lymphocytes, which represent th
106 summary, this study shows that Notch1 has an oncogenic potential in the brain when combined with othe
107 AR signaling, providing further insight into oncogenic potential in the development of HCC in HCV-inf
108 ngs establish that VavP-driven MYC has broad oncogenic potential in the hematopoietic compartment and
109 dicating that E6 has a weaker but detectable oncogenic potential in the reproductive tract compared w
110 nt reductions in tumor formation in vivo and oncogenic potential in vitro were observed in late gener
111 to activation of the pathway and N217I shows oncogenic potential in vitro.
112  the anticancer drug dasatinib on Src kinase oncogenic potential in vivo We further show that myristo
113 ies in vitro, suggesting that differences in oncogenic potential in vivo were due to host responses t
114 ion and/or excessive levels of Tbx3 may have oncogenic potential in vivo.
115 rate here that SV40 isolates differ in their oncogenic potentials in Syrian golden hamsters.
116 mosome arms, some of which harbor genes with oncogenic potential, including USP17L2 (DUB3), BRF1, MTA
117 of mTR into cells significantly restored the oncogenic potential, indicating telomerase activation is
118              These studies indicate that the oncogenic potential inherent in antigen receptor diversi
119                                              Oncogenic potential is associated with translational reg
120 t-derived clear cell sarcoma cell line whose oncogenic potential is driven by a chimeric protein EWS-
121 s2:ERG variants reveals that their different oncogenic potential is impacted by the status of the Ets
122                                        ERG's oncogenic potential is well known because of its involve
123 s (EBV) latent infection, and its associated oncogenic potential, is dependent on genome maintenance
124  active cell division for gene transduction, oncogenic potential, low titers and gene silencing.
125  suggest that dex responsiveness, along with oncogenic potential, may provide a possible explanation
126                                It has strong oncogenic potential, mutated or virally transduced forms
127 sion of genes involved in tumor genesis, the oncogenic potential of 2-hydroxyglutarate, the impact on
128                     Demonstrating the direct oncogenic potential of a cdc25 gene, we identify a gain-
129                        Here we show that the oncogenic potential of a point mutant of Myc (MycV394D)
130 tory proliferation and prevent the intrinsic oncogenic potential of a tissue regeneration program.
131 Abl-interacting proteins that antagonize the oncogenic potential of Abl after overexpression in fibro
132                              We explored the oncogenic potential of activated Notch1 in the lung by d
133 USP5 as a tumor suppressor by modulating the oncogenic potential of activated Ras in the epidermis.
134 ling in fibroblasts modulates the growth and oncogenic potential of adjacent epithelia in selected ti
135  this finding, and our observations that the oncogenic potential of Akt correlates with its effect on
136 odel of malignant melanoma, we show that the oncogenic potential of apoptotic tumor cells extends bey
137  monoclonal antibodies to assess further the oncogenic potential of Axl.
138 rmal enzymatic activation is critical to the oncogenic potential of Bcr-Abl.
139                                          The oncogenic potential of bic, particularly its ability to
140                        Here, we examined the oncogenic potential of Bmi-1 in MCF10A cells, a spontane
141 nism by which ARF specifically restrains the oncogenic potential of c-Myc without affecting its norma
142 ng that Thr-58 phosphorylation restricts the oncogenic potential of c-Myc.
143 NA resulted in a significant reversal of the oncogenic potential of cadmium-transformed Balb/c-3T3 ce
144 embrane region appear to be critical for the oncogenic potential of CD98hc and provide a novel mechan
145                        Here, we explored the oncogenic potential of cellular Rel/NF-kappaB proteins i
146  damage-induced apoptosis in suppressing the oncogenic potential of chromosome breaks.
147                    Here, we investigated the oncogenic potential of constitutive Notch2 signaling in
148 s and that this is essential to suppress the oncogenic potential of CRAF in these cells.
149  supporting this hypothesis includes (a) the oncogenic potential of CrkL versus the absence of this p
150        Secondary genetic events increase the oncogenic potential of cyclin D1 and frequently inactiva
151 in human cancer, thus further supporting the oncogenic potential of DeltaNp63alpha.
152  These data suggest that Chk2 suppresses the oncogenic potential of DNA damage arising during S and G
153                         We conclude that the oncogenic potential of double-strand breaks resulting fr
154                   These data demonstrate the oncogenic potential of dysregulated expression of a STAT
155 ution to the regulation of cell fate and the oncogenic potential of E2A-HLF.
156 e and long-term phenotypes indicative of the oncogenic potential of E6 and E7 including epithelial hy
157 is studies, there was a complete loss of the oncogenic potential of E6 in mice nulligenic for E6AP.
158 h of these many activities contribute to the oncogenic potential of E7.
159 V infection, they do not enhance the overall oncogenic potential of EBV in vivo.
160  family and contributes substantially to the oncogenic potential of EBV through activation of nuclear
161                                          The oncogenic potential of ectopic Runx expression has been
162 sic juxtamembrane sequence in regulating the oncogenic potential of EGFR signaling.
163                                         This oncogenic potential of eIF3h is enhanced by phosphorylat
164                                              Oncogenic potential of ErbB2 is linked to inefficient en
165              It has been postulated that the oncogenic potential of FOXM1 is determined by its capaci
166 ocussed on an increased understanding of the oncogenic potential of galactic cosmic rays.
167 g to rapidly and effectively interrogate the oncogenic potential of genomic rearrangements identified
168 172 and 182, which are known to increase the oncogenic potential of HBV.Finally, >/=1 drug resistance
169                    These findings extend the oncogenic potential of HBZ and suggest that viral expres
170 ing an environment fertile for the long-term oncogenic potential of HCV.
171          There is emerging evidence that the oncogenic potential of hdm2 (human and/or murine double
172 ity of PTPN13, and consequently elevated the oncogenic potential of Her2 and the invasiveness of Her2
173 age response pathway normally attenuates the oncogenic potential of HPV16 E7.
174                         The distribution and oncogenic potential of HPV58 variants appear to be heter
175                            We also show that oncogenic potential of Hsp72 is confined in its peptide
176 32, pp32r1 and pp32r2 genes may modulate the oncogenic potential of human prostate cancer.
177                Since STP is required for the oncogenic potential of HVS, we investigated the function
178  the first time, unambiguous evidence of the oncogenic potential of IEX-1 in a cell-specific manner.
179           In this study, we investigated the oncogenic potential of IGF-2 in IGF2-overexpressing CRC
180                           In addition to the oncogenic potential of its viral proteins, HBV, as a DNA
181 ressor pathway, which probably restricts the oncogenic potential of K cyclin.
182               These findings demonstrate the oncogenic potential of kaposin and suggest its possible
183                                To assess the oncogenic potential of LANA and kCYC, primary human umbi
184                                          The oncogenic potential of latent Epstein-Barr virus (EBV) c
185 ications regarding the genomic targeting and oncogenic potential of lp(A2).
186                                          The oncogenic potential of many nonacute retroviruses is dep
187 ressing keratinocytes completely negates the oncogenic potential of matriptase.
188 xpression of Smad4 significantly reduced the oncogenic potential of MC38 and SW620 cells; in these tr
189  enhancer elements are required for the full oncogenic potential of MCF 247-W.
190 avour cell proliferation and may explain the oncogenic potential of mdm2 when over-expressed in cells
191                  This property underlies the oncogenic potential of MDM2, which is overexpressed in v
192 fore, we determined the role of COX-2 on the oncogenic potential of MEK1 in nontransformed rat intest
193                           To investigate the oncogenic potential of Mer in vivo, we created a transge
194 a cells from NF2 patients and suppresses the oncogenic potential of Merlin-deficient tumor cell lines
195 ng-specific expression of miR-31 to test the oncogenic potential of miR-31 in the lung.
196 MTD/H1) and distal H2 domain to activate the oncogenic potential of MLL.
197 tivation domain per se does not activate the oncogenic potential of MLL.
198 ence of human herpesvirus 7 may increase the oncogenic potential of moderate-risk human papillomaviru
199                      This study confirms the oncogenic potential of mTOR suggested previously and dem
200        In the present study, to decipher the oncogenic potential of MUC4, we stably expressed the MUC
201                                          The oncogenic potential of mutant IDH2 correlated with the a
202 ndent RAF activation and is required for the oncogenic potential of mutant RAFs.
203 nic mice to normal levels, and show that the oncogenic potential of Myc in this context is suppressed
204                                          The oncogenic potential of MYC stems from its ability to bin
205 ut not Bak, eliminates all restraints to the oncogenic potential of Myc, allowing the rapid and synch
206  the major intrinsic pathway that limits the oncogenic potential of Myc.
207 ese results provided evidence supporting the oncogenic potential of NFAT3 and suggested that CDK3-med
208                                  To test the oncogenic potential of Notch1 in solid tumors, we expres
209 d describes a general strategy to define the oncogenic potential of novel glioma-associated genomic r
210                                 However, the oncogenic potential of NS remains unclear, as imbalanced
211 n endothelial cells in vivo, and unmasks the oncogenic potential of other HHV-8 genes in a paracrine
212 me for p110beta and indicate Ras-independent oncogenic potential of p110delta.
213      The translocation process increased the oncogenic potential of Pax3 by removing the inhibitory a
214 ng the essential roles of these sites in the oncogenic potential of PLAG proteins.
215 this is an unpredictable and rare event, the oncogenic potential of polyomavirus is primarily evaluat
216  Our engineered mouse models demonstrate the oncogenic potential of pseudogenes and indicate that ceR
217                                          The oncogenic potential of PSF-TFE3 became evident by stable
218 l 3-kinase (PI3-K) drastically inhibited the oncogenic potential of R-Ras.
219                       To directly assess the oncogenic potential of Rac1b in vivo, we employed a mous
220 P in the senescence response that limits the oncogenic potential of ras has provided a mechanistic ba
221 it has become clear that the activity or the oncogenic potential of Ras is dependent on the nonrecept
222  protein concentration may contribute to the oncogenic potential of receptor tyrosine kinases, and pe
223  work, we have proposed that Chk2 limits the oncogenic potential of replication-associated DNA damage
224                                 To study the oncogenic potential of Rgr in vivo, we have generated se
225 e purpose of this study was to determine the oncogenic potential of RON in vivo in lung epithelial ce
226                             We establish the oncogenic potential of ROR1-DNAJC6 and CEP85L-ROS1 fusio
227  retroviral insertional mutagenesis, and the oncogenic potential of Runx2 has been confirmed in trans
228 t induction of Sna1 may serve to amplify the oncogenic potential of Shh pathway activation through N-
229                                 However, the oncogenic potential of SLPI in prostate cancer remains u
230                               In view of the oncogenic potential of STAT3, we further examined its bi
231               We previously demonstrated the oncogenic potential of Stat5, with thymic lymphoblastic
232 Taken together, our data now demonstrate the oncogenic potential of steroid receptors and implicate a
233       The molecular mechanism underlying the oncogenic potential of SYT-SSX1/2 is not clear.
234 on, the t-Darpp/Akt axis underscores a novel oncogenic potential of t-Darpp in gastric carcinogenesis
235             We have recently reported on the oncogenic potential of TACC3; however, the molecular mec
236 IF3 mRNA resulted in significant reversal of oncogenic potential of the CdCl(2)-transformed BALB/c-3T
237  protein levels and may normally control the oncogenic potential of the DeltaNp73 isoform.
238 tion has been suggested to contribute to the oncogenic potential of the estrogen receptor alpha (ERal
239                                              Oncogenic potential of the Hedgehog pathway is mediated
240                   To further investigate the oncogenic potential of the JCV early protein in vivo, tr
241 esults provided direct evidence for the anti-oncogenic potential of the NFAT3 transcription factor.
242  and thereby provide direct evidence for the oncogenic potential of the NFATc1 transcription factor.
243                                 The dominant oncogenic potential of the PAX3-FKHR fusion protein is d
244                                 Although the oncogenic potential of the PI3-kinase subunit p110alpha
245        Numerous studies have highlighted the oncogenic potential of the predominant p63 isoform Delta
246 blastic leukemias (B-ALLs), illustrating the oncogenic potential of the RAG complex.
247                  These results elucidate the oncogenic potential of the Runx family and reveal novel
248       However, upon mounting evidence of the oncogenic potential of the viral regulatory protein, T-a
249 replication in vivo, and severely limits the oncogenic potential of the virus.
250 gen (T-Ag), which is believed to mediate the oncogenic potential of the virus.
251                               The surprising oncogenic potential of the wild-type non-alpha isoforms
252                                          The oncogenic potential of these effector pathways is illust
253 e models are critical tools to determine the oncogenic potential of these genes.
254 nd Bcl-3 are discussed that may underlie the oncogenic potential of these proteins, as evidenced by r
255 /ErbB receptor family frequently release the oncogenic potential of these receptors, resulting in the
256           In this study, we investigated the oncogenic potential of these somatic mutations by establ
257 man mammary epithelial cells, confirming the oncogenic potential of this mutation.
258                                 However, the oncogenic potential of this nucleophosmin mutant (NPMc+)
259 is KSHV miRNA is likely to contribute to the oncogenic potential of this opportunistic viral pathogen
260 ous system (CNS) and non-CNS origin, and the oncogenic potential of this virus in several laboratory
261                                          The oncogenic potential of this virus is mediated by a trans
262 ht into how C-terminal deletion triggers the oncogenic potential of TPL-2 by rendering its kinase act
263 d be expected to directly correlate with the oncogenic potential of transformed cells.
264 dependent up-regulation of CAV1 enhanced the oncogenic potential of tumor cells by increasing the cel
265                             Importantly, the oncogenic potential of UBASH3B is dependent on its tyros
266                                          The oncogenic potential of v-mpl may arise from deletion of
267                               The aggressive oncogenic potential of v-Rel has arisen from multiple mu
268         To determine the biologic effect and oncogenic potential of Vav1 in hematopoietic lineages, w
269 cells expressing oncogenic Vav1, and suggest oncogenic potential of Vav1-mediated pathways in primary
270 ct to that of somatic KIT D816V disease, the oncogenic potential of which might be influenced by SCF
271 t the YAP-TEAD interaction and to reduce the oncogenic potential of YAP.
272 p are mediated through the repression of the oncogenic potentials of AUF1.
273 as an antagonist to the growth-promoting and oncogenic potentials of tyrosine kinase.
274 t model system for studying the biology, and oncogenic potential, of Runx genes.
275 receptor tyrosine kinases have complementary oncogenic potential, or because of heterogeneity in the
276            In spite of assumptions about its oncogenic potential, prior efforts to demonstrate that m
277   Our results identify CARD11 mutations with oncogenic potential, provide a mechanistic explanation f
278 se response that needs to be bypassed before oncogenic potential ras can be revealed.
279 yrosine (Y394) increases kinase activity and oncogenic potential regardless of regulatory C-terminal
280 of c-Fos and c-Jun contributes to its weaker oncogenic potential relative to v-Rel.
281           However, the mechanism behind this oncogenic potential remains elusive.
282 6, its specific biological niche, and/or its oncogenic potential remains to be established.
283 ogenesis of this disease, but its functional oncogenic potential remains uncertain.
284 r-specific chromosomal rearrangements, whose oncogenic potential remains unknown.
285                                         This oncogenic potential requires kinase activity and can be
286 inase (NPM-ALK), which possesses significant oncogenic potential resulting from the constitutive acti
287       PELs harboring two viruses have higher oncogenic potential, suggesting functional interactions
288          TC21 is a Ras-like GTPase with high oncogenic potential that is found mutated in some human
289 umor suppressor function, apoptosis also has oncogenic potential that is regulated by the extent of M
290                    Because both viruses have oncogenic potential, their role in the development of BR
291 osis and suggests that Wnt-1 may exhibit its oncogenic potential through a mechanism of anti-apoptosi
292  report showing that v-Rel might execute its oncogenic potential through modulating the activity of e
293 e that JAK3 (M511I) can increase its limited oncogenic potential through the acquisition of an additi
294 t in certain cellular contexts, WT1 exhibits oncogenic potential through the transcriptional upregula
295 P in transformation progression and link its oncogenic potential to EphA2.
296                                          Its oncogenic potential was further demonstrated by its abil
297                                 To study the oncogenic potential, we generated mouse embryonic fibrob
298  We previously have shown that KSHV-GPCR has oncogenic potential when overexpressed in fibroblasts an
299 e we show that matriptase possesses a strong oncogenic potential when unopposed by its endogenous inh
300            The viral Kaposin locus has known oncogenic potential, which has previously been attribute

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top